View More

Participates in WHX Dubai 2026, Accelerates Middle East Med-Robotics Expansion

•  Showcases CUVIS-joint Surgical Robot and Morning Walk Rehabilitation Robot, Expands Middle East Network Medical robotics specialist CUREXO(060280) announced on the 13th that it successfully participated in WHX Dubai 2026, the world's largest medical device exhibition, held from the 9th to the 12th in Dubai, UAE.Visitors listen to an explanation of the Morning Walk gait rehabilitation robot at the Curexo booth during WHX Dubai 2026. [Photo courtesy of Curexo]  WHX Dubai 2026 (World Health Expo Dubai) is a leading global healthcare exhibition representing the Middle East region, attracting medical device companies, healthcare professionals, and industry stakeholders from around the world. At the exhibition, CUREXO showcased its flagship products: the CUVIS-joint robotic system for joint replacement surgery and the Morning Walk gait rehabilitation robot. During the exhibition, the company's booth received visits from medical device distributors and healthcare institution representatives across the Middle East and Africa. Based on live demonstrations, discussions were held regarding potential equipment adoption and partnership opportunities. Through these meetings, the company confirmed the potential for expanding its local partnership network in the Middle East. In particular, CUREXO shared its global business roadmap, including its goal of obtaining CE MDR certification in Europe this year, further strengthening partner confidence. CE MDR certification represents enhanced safety and quality standards required not only in Europe but also in key overseas markets such as the Middle East. Securing the certification is expected to serve as a critical turning point for expanding global sales. A CUREXO official stated, "The Middle East is a strategic market where government-led healthcare investment and demand for advanced medical services are rapidly increasing. Building on this exhibition, we will accelerate our expansion into the Middle East medical robotics market and further drive overseas revenue growth."

View More

Indian Subsidiary Secures Medical Device Import License, Expands Local Supply and Service

•  Localization of Core Parts and Consumables Supply Chain … Establishment of Local Supply and After-Sales Service SystemCUREXO Inc., a medical robotics company led by CEO Lee Jae-jun, announced on the 13th that its Indian subsidiary has obtained a Medical Device Import License (MD-15) from the Central Drugs Standard Control Organization (CDSCO) for its robotic joint surgery system, CUVIS-joint."CUVIS-joint" (Photo courtesy of CUREXO) This approval is a mandatory requirement for the importation of medical devices into India and is significant in that it enables the local subsidiary to directly supply the robotic system, as well as related consumables and core components. With the acquisition of the license, CUREXO has established a system under which its Indian subsidiary can directly import and manage consumables and key components, for which demand is increasing in line with the growing number of surgical procedures. This is expected to shorten delivery lead times for consumables in India, enhance inventory responsiveness, and ultimately improve the operational stability and convenience of robotic surgery programs at medical institutions. In addition, the local subsidiary will serve as a service hub, providing equipment maintenance and technical support to distributors and healthcare institutions. The company stated that establishing a localized response system that integrates parts supply and technical support will help enhance equipment uptime and customer satisfaction, thereby laying the groundwork for future revenue growth. A CUREXO official commented that the acquisition of the import license is meaningful in that it provides a stable foundation for the Indian subsidiary to carry out local supply and service functions, adding that the company will continue to strengthen its local capabilities to enhance business stability in the Indian market.

View More

CUVIS-Joint THA Achieves Clinical Success in Hip Replacement Surgery in Korea

•  Bumin Hospital President Dr. Yong-Chan Ha Performs Korea's First Successful Hip Replacement Using a Domestic Medical Robot•  Indication Expanded from Knee to Hip, Demonstrating an Expandable Surgical Platform CUREXO, a medical robotics company led by CEO Jae-Jun Lee, announced on the 10th that it has successfully completed a total hip arthroplasty (THA) using CUVIS-Joint THA, marking the first successful clinical hip replacement performed by a Korean medical robotics company. The surgery was performed at Seoul Bumin Hospital by Dr. Yong-Chan Ha, President of the hospital and a nationally and internationally recognized authority in hip surgery. This procedure is particularly significant as it represents the first clinical success by a domestic medical robotics company for the THA indication using CUVIS-Joint."Dr. Yong-Chan Ha of Seoul Bumin Hospital is performing hip replacement surgery using Curexo's CUVIS-Joint THA." CUVIS-Joint THA establishes a three-dimensional preoperative surgical plan based on the patient's anatomical structure and enables highly precise bone resection through robotic assistance. This approach minimizes key variables in hip replacement surgery—such as implant positioning errors and leg length discrepancies—thereby maximizing surgical accuracy and consistency. CUREXO has already led the commercialization of domestically developed orthopedic surgical robots through CUVIS-Joint for knee replacement procedures. With this successful hip replacement surgery, the company has expanded its application from the knee to the hip. This achievement demonstrates that CUVIS-Joint is an expandable surgical platform capable of supporting multiple joint replacement procedures within a single robotic system. Dr. Ha stated, "This clinical case is highly meaningful in that it proves, through real-world practice, that Korean-developed surgical robots are capable of performing complex hip surgeries with a high level of precision. As surgical data continues to accumulate, CUVIS-Joint has the potential to drive transformative changes across the field of orthopedic surgery." A CUREXO representative added, "CUVIS-Joint THA is a solution designed to maximize precision in complex hip replacement procedures. Having demonstrated our robotic capabilities in both knee and hip surgeries, we will continue striving to become a global leader in the orthopedic surgical robotics market."

View More

CUREXO Hosts Global Webinar on Gait Rehabilitation Robot 'MorningWalk'

• Sharing rehabilitation research outcomes with Seoul National University, Charité – Universitätsmedizin Berlin and UTMB• Presenting advanced rehabilitation solutions integrating BCI and VR technologies Medical robot specialist CUREXO Inc. (CEO: Jae Jun Lee) announced that it held a global webinar on the 17th to share domestic and international research outcomes related to its gait rehabilitation robot system, MorningWalk. The webinar, d "MorningWalk: Redefining the Future of Gait Rehabilitation Robotics," was organized to discuss research trends and clinical applications in the field of robotic gait rehabilitation. The event brought together CUREXO researchers and experts in rehabilitation robotics from leading universities and medical institutions, including Seoul National University, Charité – Universitätsmedizin Berlin, and a Texas medical school. Participants presented on the future direction of robotic gait rehabilitation technology and its therapeutic effectiveness in real clinical settings. During the webinar, collaborative research cases were shared that integrate advanced technologies—such as brain-computer interfaces (BCI), soft wearable robots, and virtual reality (VR)-based propulsion force feedback training—with CUREXO's MorningWalk system. [Photo 1 = CUREXO] 2025 MorningWalk Webinar CUREXO 's MorningWalk is an end-effector–based gait rehabilitation robot that provides customized rehabilitation training for pediatric to adult patients with various conditions, including stroke, spinal cord injury, and Parkinson's disease. Notably, it features a seated body-weight support system that reduces patient setup time to under three minutes. The system also enhances training efficiency by simulating not only level-ground walking but also stairs and slopes, enabling diverse gait environments. A CUREXO representative stated, "This webinar was a meaningful opportunity to share domestic and international research cases utilizing MorningWalk and to confirm its clinical effectiveness in the field of robotic gait rehabilitation. We will continue to advance gait rehabilitation robot technology and expand clinical applications through collaboration with global medical professionals and researchers."

View More

CUREXO Turns Profitable in Q3 and Diversifies Global Medical Robot Revenue Base

• Cumulative sales of KRW 53.7 billion, up 30% year-on-year• Medical robot segment revenue up 80% year-on-year• Sales network expanded to Japan, Taiwan, Indonesia, Malaysia and PakistanSeoul, Republic of Korea – CUREXO Inc. (KOSDAQ: 060280), a medical robotics specialist, announced that it recorded an operating profit of KRW 9.7 billion on a consolidated basis in the third quarter, turning profitable compared with the same period last year.The company reported cumulative consolidated sales of KRW 53.7 billion for the first three quarters, representing a 30% increase year-on-year. In particular, cumulative revenue from its core medical robot business grew by 80% over the same period last year, driving both top-line growth and improved profitability.Operating profit for the third quarter came in at KRW 9.7 billion, marking a turnaround from both the prior-year quarter and the previous quarter and signaling a clear improvement in earnings quality.CUREXO explained that its performance was primarily supported by the diversification of its global medical robot sales portfolio. In 2024, the company expanded sales into new overseas markets including Japan, Taiwan, Indonesia, Malaysia and Pakistan, thereby broadening and stabilizing its international revenue base. The company also noted that sales in India, which were temporarily sluggish last year, have started to recover.A CUREXO spokesperson said,"Once we obtain regulatory approvals for CUVIS-joint in the United States (FDA), Europe (CE), and in markets such as the Middle East and Latin America, we expect to generate additional medical robot sales. We will continue to expand our presence in global markets and aim to maintain mid- to long-term growth momentum."

View More

CUREXO Secures Domestic Approval for Total Hip Arthroplasty (THA) Robot 'CUVIS-joint THA'

• Expansion of Indications from Knee to Hip Surgerical Robots… Enhanced Surgical Accuracy and Convenience with AI Medical robotics company CUREXO announced on the 2nd that it has obtained product approval from the Ministry of Food and Drug Safety (MFDS) for its total hip arthroplasty (THA) surgical robot, "CUVIS-joint THA." With this approval, CUREXO has expanded its product portfolio by adding hip indications to its existing knee joint replacement surgical robot, "CUVIS-joint." CUVIS-joint THA is equipped with AI-based automatic segmentation of hip CT images, surgical planning software, precision robotic control technology, and a user-friendly UI to enhance surgical convenience. (CUVIS-joint THA, photo = CUREXO) Based on this domestic approval, CUREXO plans to accelerate its global market entry by also pursuing overseas certifications, including the U.S. FDA and European CE approval for hip surgery. A CUREXO representative stated, "By integrating AI and robotic control technology, we have improved surgical accuracy and user convenience. We will continue to invest in R&D to strengthen our competitiveness in the global surgical robot market."

View More

CUREXO Supplies "CUVIS-joint" Artificial Joint Surgery Robot to Indonesia's Largest Hospital

• Expanding Global Presence with Advanced Medical Robotics Seoul, Korea – CUREXO, Inc. (CEO: Jae-Jun Lee), a leading medical robotics company, announced that it has successfully supplied its CUVIS-joint, an artificial joint surgical robot, to Indonesia's largest hospital.CUVIS-joint is designed to support surgeons in performing precise joint replacement surgeries by providing accurate preoperative planning and optimized surgical guidance. Through advanced 3D modeling, the system enables tailored surgical plans for individual patients, improving accuracy, consistency, and overall outcomes. The adoption of CUVIS-joint by Indonesia's largest hospital marks an important step in expanding access to cutting-edge robotic surgery across Southeast Asia. With the increasing demand for joint replacement procedures in the region, the introduction of this innovative solution is expected to significantly enhance surgical quality and patient recovery. A CUREXO spokesperson stated: "By supplying CUVIS-joint to Indonesia's leading hospital, we are accelerating our global expansion strategy. We will continue to strengthen our presence in international markets, providing innovative solutions that advance surgical precision and improve patient quality of life." CUREXO currently offers a diverse portfolio of advanced medical robots, including the CUVIS-spine, a spine surgical robot, and the Morning Walk, a rehabilitation robot. With proven technology and clinical performance, the company continues to solidify its leadership in the global medical robotics market.

View More

CUREXO Initiates Clinical Trials of "CUVIS-Spine" for National Health Insurance Reimbursement in Korea

• Designated as Innovative Medical Technology in April 2024; First Clinical Trial Successfully Conducted at Severance HospitalSeoul, Korea – April 11, 2024 – CUREXO, Inc. (CEO: Jae-Jun Lee), a leading medical robotics company, announced that its spine surgical robot, CUVIS-Spine, has been successfully utilized in its first clinical trial at Severance Hospital, Seoul.CUVIS-spine was designated as an Innovative Medical Technology in April 2024 by the National Evidence-based Healthcare Collaborating Agency (NECA). The designation allows advanced technologies with high potential and innovation to be introduced into clinical practice under certain conditions, facilitating early market entry and evaluation.The trial at Severance Hospital marks the first clinical case conducted under this designation and represents a critical milestone toward securing national health insurance reimbursement. Additional clinical trials are also planned at Pusan National University Yangsan Hospital, with IRB approval procedures currently underway.Designed to assist surgeons in accurately guiding and securing pedicle screws, CUVIS-spine integrates advanced 3D imaging devices (O-arm, 3D C-arm) and 2D imaging devices (C-arm). The system offers significant advantages over conventional methods, including:• •  Enhanced pedicle screw placement accuracy•  Reduced surgical time•  Shortened patient recovery periodA CUREXO spokesperson commented: "Through clinical trials at leading tertiary hospitals, we aim to accelerate the registration of CUVIS-spine as a new medical technology and its inclusion in the national health insurance system. Having obtained approvals from the U.S. FDA, European CE, and Korean MFDS, the safety and efficacy of CUVIS-spine are already validated globally. We are confident that this technology will drive meaningful innovation in spine surgery both in Korea and worldwide." In addition to CUVIS-spine, CUREXO also offers the CUVIS-joint, an artificial joint surgical robot, and the Morning Walk, a rehabilitation robot. The company continues to strengthen its presence in the global medical robotics market through advanced technology and proven clinical performance.

View More

CUREXO and The University of Texas Medical Branch Jointly Develop World's First Propulsion Force Feedback System for Rehabilitation Robots

• Real-time ground reaction force feedback helps improve gait symmetry in patients with moderate to severe impairments • Immersive VR-based training enhances patient engagement and motivation CUREXO, a leading medical robotics company (CEO Jaejun Lee), announced that it has co-developed a new Propulsion Force Feedback (PFF) system for its gait rehabilitation robot MORNINGWALK, in collaboration with The University of Texas Medical Branch (UTMB). This groundbreaking feature is the world's first system to provide real-time analysis of anterior-posterior ground reaction force (GRF), offering patients intuitive feedback on their gait propulsion.< Propulsion Force Feedback System > The newly developed PFF system is designed to move beyond conventional passive rehabilitation methods, enabling patients to engage in more active and goal-oriented training. It is particularly effective for stroke patients who typically exhibit significantly reduced GRF. By enhancing propulsion on the affected (hemiparetic) side, the system helps restore gait symmetry and improve walking stability. In addition, the system incorporates an interactive VR-based training program, transforming repetitive rehab exercises into an engaging, game-like experience. Patients can visually monitor their propulsion force in real time and make immediate adjustments, maximizing the effectiveness of each session.< VR System > "Gait propulsion is not only a measure of mobility but also a key indicator of a patient's ability to return to independent daily life," said a CUREXO spokesperson. "With the MORNINGWALK PFF system, medical professionals can design more precise rehabilitation strategies while patients train with increased motivation and enjoyment."The MORNINGWALK is an end-effector type gait rehabilitation robot, which assists lower limb joints through a powered footplate system. It is currently being utilized in major hospitals across South Korea and internationally recognized medical institutions.